All News
EULAR 2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
Risk of haematological malignancy in PsA
Nordic cohorts
*40 events, IR 67/100 000 person-years
*NO difference between PsA bionaive and TNFi treated
BUT *⬆️ in PsA vs. matched controls
*no difference between myeloid and lymphoid malignancies.
OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3
Aurelie Najm AurelieRheumo ( View Tweet)
Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh
Dr. Antoni Chan synovialjoints ( View Tweet)
Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose):
⭐️ACR50 52%
⭐️PASI 90 50%
⭐️Resolution of enthesitis LEI 88%
⭐️Safety profile similar to what observed in PsO.
Promising for the enthesitis domain!
@RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP
Aurelie Najm AurelieRheumo ( View Tweet)
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
Dr. Antoni Chan synovialjoints ( View Tweet)
Updates in Psoriatic Arthritis at EULAR 2022. Here are the topics I will be highlighting at the conference #psoriaticarthritis #EULAR2022 @RheumNow https://t.co/8Dd29GdUuz
Dr. Antoni Chan synovialjoints ( View Tweet)
WATCH: Can Dermatologists Help Detect Psoriatic Arthritis?
Dr. Robert Chao reviews abstract OP0029 presented at #EULAR2022 in June.
https://t.co/bAuCsVLJV2 https://t.co/BjUckSXIJ3
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in disease activity when compared to MTX monotherapy. As expected, MTX+LEF less well tolerated.
@RheumNow #EULAR2022 ABST#0078 https://t.co/Bo64QX3Bf9
Robert B Chao, MD doctorRBC ( View Tweet)
Depression was the most prevalent comorbidity (31%), hypertension (26%) and uveitis the most common EMM (30%) in AS from the PSOAS cohort by @rheum_cat .
Five clusters identified with depression and hypertension groups having higher disease activity #EULAR2022 @RheumNow OP0154 https://t.co/dpqaFD4Qzw
Dr. Antoni Chan synovialjoints ( View Tweet)
Risk factors associated with non-remission/LDA in PsA pts:
Baseline TJC>3, SJC>5
CRP>10
HAQ>0.5
enthesitis/dactylitis
BMI>30
sDMARD use
@RheumNow #EULAR2022 ABST#POS0080
Robert B Chao, MD doctorRBC ( View Tweet)
Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well..
@RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ
Robert B Chao, MD doctorRBC ( View Tweet)
Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu
Richard Conway RichardPAConway ( View Tweet)
Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074
Robert B Chao, MD doctorRBC ( View Tweet)
Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts.
@RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC
Robert B Chao, MD doctorRBC ( View Tweet)
Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6
Richard Conway RichardPAConway ( View Tweet)
Does MTX have an impact on UST-immunogenicity in PsA?
Post-hoc analysis from UST RCT in 110+ pts
No difference in ADA rates & concentrations between
MTX and non-MTX groups and
ADA not associated w/ decreased UST levels
POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT
Aurelie Najm AurelieRheumo ( View Tweet)
2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt
Richard Conway RichardPAConway ( View Tweet)
☄️ Biomarkers substudies of COSMOS & DISCOVER-1 RCT GUS in PsA:
TNFi-IR pts have a different plasma signature w/ higher BL IL-22 & TNF
*Association between BL IL-22 levels & W24 PASI75
and trend for BL IL-22 levels & W24 ACR20
#EULAR2022 @RheumNow POS0074 @StefanSiebert1 https://t.co/Midtug4NJO
Aurelie Najm AurelieRheumo ( View Tweet)
All the domains of sexual sphere are deteriorated in RA and PsA.
This aspect is often overlooked and can have a significant impact on pts QoL. It may be time to assess this aspect more specifically using CSFQ-14 and propose dedicated interventions. #OP0139 @RheumNow #EULAR2022 https://t.co/l0zyBIZ1LI
Aurelie Najm AurelieRheumo ( View Tweet)
The GESPIC cohort reports in Axial PsA, 75% had inflammatory back pain, 45% met NY criteria for AS, 55% with active inflammatory change in SI joint and 60% in the spine. This is where the overlap between Axial PsA and Axial SpA happens, Kading et al #EULAR2022 @RheumNow OP0026
Dr. Antoni Chan synovialjoints ( View Tweet)
